Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

101. Multiple sclerosis: Corticosteroids

Multiple sclerosis: Corticosteroids Corticosteroids | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Corticosteroids Multiple sclerosis: Corticosteroids Last revised in October 2019 Corticosteroids For detailed prescribing information on oral corticosteroids, see the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

102. Multiple sclerosis: Dantrolene

Multiple sclerosis: Dantrolene Dantrolene | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Dantrolene Multiple sclerosis: Dantrolene Last revised in October 2019 Dantrolene What doses of dantrolene are indicated for spasticity? The dose of dantrolene often needs adjustment for each person, but a typical regimen is: Initial dose: 25 mg daily. Titration: gradually increase the dose at intervals of at least one week. Typically, it is not usual to have to exceed 75 mg

2018 NICE Clinical Knowledge Summaries

103. Multiple sclerosis: Benzodiazepines

Multiple sclerosis: Benzodiazepines Benzodiazepines | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Benzodiazepines Multiple sclerosis: Benzodiazepines Last revised in October 2019 Benzodiazepines For prescribing information on benzodiazepines, see the section in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

104. Multiple sclerosis: Scenario: Managing the major symptoms and complications of multiple sclerosis

Multiple sclerosis: Scenario: Managing the major symptoms and complications of multiple sclerosis Scenario: Managing complications | Management | Multiple sclerosis | CKS | NICE Search CKS… Menu Scenario: Managing complications Multiple sclerosis: Scenario: Managing the major symptoms and complications of multiple sclerosis Last revised in October 2019 Scenario: Managing the major symptoms and complications of multiple sclerosis From age 18 years onwards. Which complications should be managed (...) in primary care? Many of the complications of multiple sclerosis will be managed by a specialist multidisciplinary team. Consider liaising with members of the multidisciplinary team when taking decisions on management. However, depending on local arrangements and local guidelines, primary care practitioners may have a role to play in the management of a number of symptoms and complications including: How should I manage fatigue in a person with multiple sclerosis? Assess the person for anxiety

2018 NICE Clinical Knowledge Summaries

105. Multiple sclerosis: Amitriptyline

Multiple sclerosis: Amitriptyline Amitriptyline | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Amitriptyline Multiple sclerosis: Amitriptyline Last revised in October 2019 Amitriptyline For prescribing information, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

106. Multiple sclerosis: Baclofen

Multiple sclerosis: Baclofen Baclofen | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Baclofen Multiple sclerosis: Baclofen Last revised in October 2019 Baclofen What doses of baclofen are indicated for spasticity? The dose of baclofen often needs adjustment to suit each person, but a typical regimen is: Initial dose: 5 mg three times a day. Titration: gradually increase the dose every three days. Typical maintenance dose is 60 mg daily in divided doses. Maximum

2018 NICE Clinical Knowledge Summaries

107. Multiple sclerosis: Amantadine

Multiple sclerosis: Amantadine Amantadine | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Amantadine Multiple sclerosis: Amantadine Last revised in October 2019 Amantadine What doses of amantadine are indicated for fatigue? The use of amantadine for fatigue in people with multiple sclerosis (MS) is off-label. The dose most commonly used in the studies evaluating amantadine for MS-related fatigue is 100 mg twice daily. [ ; ] What are the contraindications

2018 NICE Clinical Knowledge Summaries

108. Multiple sclerosis: When should I suspect that a person has multiple sclerosis?

Multiple sclerosis: When should I suspect that a person has multiple sclerosis? Initial presentation | Diagnosis | Multiple sclerosis | CKS | NICE Search CKS… Menu Initial presentation Multiple sclerosis: When should I suspect that a person has multiple sclerosis? Last revised in October 2019 When should I suspect that a person has multiple sclerosis? Multiple sclerosis (MS) can affect nearly any part of the central nervous system. Therefore, the presenting symptoms and signs can vary greatly (...) movement abnormalities that can cause diplopia, oscillopsia (a sensation of movement of the vision), nystagmus, and internuclear ophthalmoplegia (inability to adduct one eye and nystagmus in the abducting eye on oculomotor examination). Bulbar muscle problems resulting in dysarthria or dysphagia. Basis for recommendation The information on the possible presentations of multiple sclerosis is based on the National Institute for Health and Care Excellence (NICE) guideline Multiple sclerosis: management

2018 NICE Clinical Knowledge Summaries

109. Multiple sclerosis: What else might it be?

Multiple sclerosis: What else might it be? Differential diagnosis | Diagnosis | Multiple sclerosis | CKS | NICE Search CKS… Menu Differential diagnosis Multiple sclerosis: What else might it be? Last revised in October 2019 What else might it be? No symptom or sign that may occur with multiple sclerosis (MS) is unique to MS, and other conditions often need to be ruled out, especially in the early stages of the disease. These include: Other demyelinating diseases: Neuromyelitis optica — a rare (...) brain lesions — can cause progressive neurological symptoms and signs. Paraneoplastic syndromes — may cause cerebellar ataxia and other neurological symptoms and signs. Basis for recommendation The information on differential diagnoses to consider in a person presenting with possible multiple sclerosis is based on the National Institute for Health and Care Excellence (NICE) guideline Multiple sclerosis: management of multiple sclerosis in primary and secondary care [ ], and in the review articles

2018 NICE Clinical Knowledge Summaries

110. Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis

Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis NHS England » Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages) Search Search Menu Urgent Clinical Commissioning Policy Statement: Natalizumab-induced (...) Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages) Document first published: 14 March 2018 Page updated: 14 March 2018 Topic: , Publication type: This clinical commissioning policy statement is an interim commissioning position pending the formation of a Clinical Policy. Document PDF 74 KB 5 pages

2018 NHS England

111. Mavenclad - cladribine - Multiple Sclerosis, relapsing

Mavenclad - cladribine - Multiple Sclerosis, relapsing cladribine | CADTH.ca Find the information you need cladribine cladribine Last Updated: November 27, 2018 Result type: Reports Project Number: SR0546-000 Product Line: Generic Name: cladribine Brand Name: Mavenclad Manufacturer: EMD Serono, a Division of EMD Inc., Canada Indications: Multiple Sclerosis, relapsing Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: October 24, 2018 Recommendation Type (...) Recommendation posted October 26, 2018 Final CDR review report(s) and patient input posted October 31, 2018 Tags multiple sclerosis, nervous system, multiple sclerosis, relapsing-remitting, cladribine; RRMS Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

112. Ocrelizumab (Ocrevus) - multiple sclerosis

Ocrelizumab (Ocrevus) - multiple sclerosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 9 November 2017 EMA/790835/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ocrevus International non (...) Chain LC-MS Liquid Chromatography - Mass Spectrometry; LC-UV Liquid Chromatography - Ultraviolet; LMWS Low-Molecular-Weight Species; LPA Leached Protein A LPM Liters Per Minute;. LRV Log Reduction Value MAR Multivariate Acceptable Range MCB Master Cell Bank MMV Murine Minute Virus Mn2+ Manganese MS Multiple Sclerosis MTX methotrexate NA Not Applicable NANA N-acetylneuraminic acid;; NEM N-ethylmaleimide NF National Formulary NGHC Non-glycosylated Heavy Chain. NGNA N-glycolylneuraminic acid; non-CPP

2018 European Medicines Agency - EPARs

113. Fampridine (Fampyra) in cases of multiple sclerosis (MS)

Fampridine (Fampyra) in cases of multiple sclerosis (MS) Fampridine (Fampyra®) in cases of multiple sclerosis (MS) | Report | National Health Care Institute You are here: Fampridine (Fampyra®) in cases of multiple sclerosis (MS) Search within English part of National Health Care Institute Search Fampridine (Fampyra®) in cases of multiple sclerosis (MS) Zorginstituut Nederland carried out an assessment of the medicinal product fampridine (Fampyra®). Based on the outcomes of the assessment

2018 National Health Care Institute (Zorginstituut Nederland)

114. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Multiple sclerosis Last reviewed: February 2019 Last updated: February 2019 Summary Demyelinating central nervous system condition clinically defined by two episodes of neurological dysfunction (brain, spinal cord, or optic nerves) that are separated in space and time. Classically presents in white women, aged between 20 to 40 years (...) , but lends greater specificity when present with brain lesions. Treatment of the condition can be divided into three parts: treatment of the acute attack; prevention of future attacks by reducing triggers and use of disease-modifying therapies; and symptomatic treatments of neurological difficulties such as spasticity, pain, fatigue, and bladder dysfunction. Definition Multiple sclerosis (MS) is defined as an inflammatory demyelinating disease characterised by the presence of episodic neurological

2018 BMJ Best Practice

115. Cladribine tablets for treating relapsing?remitting multiple sclerosis

Cladribine tablets for treating relapsing?remitting multiple sclerosis Cladribine tablets for treating Cladribine tablets for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

117. PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage | European Medicines Agency Search Search Menu PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage Press release 27/10/2017 Zinbryta to be used only in a restricted patient group, with strict liver monitoring (...) EMA's ( ) is recommending further restrictions on the use of the multiple sclerosis medicine Zinbryta (daclizumab) following a review of the medicine's effects on the liver. The review found that unpredictable and potentially fatal immune-mediated liver injury can occur during treatment with Zinbryta and for up to 6 months after stopping treatment. In , 1.7% of patients receiving Zinbryta had a serious liver reaction. In order to reduce the risks, doctors should now only prescribe Zinbryta

2017 European Medicines Agency - EPARs

118. Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis Full Text available with Trip Pro

Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis 29854982 2019 02 26 2468-0249 3 3 2018 May Kidney international reports Kidney Int Rep Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis. 732-737 10.1016/j.ekir.2017.11.013 George Jason C JC Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA. Mohan Prince P Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA. Ho Kevin K Department of Nephrology, Geisinger Medical Center

2017 Kidney international reports

119. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality (Abstract)

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS.We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic

2017 EvidenceUpdates

120. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Full Text available with Trip Pro

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Multiple sclerosis is a degenerative inflammatory disease of the CNS characterised by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in the CNS is a specialised extension of the oligodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyte precursor cells in vitro, in animal models (...) , and in human cells. We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis.We did this single-centre, 150-day, double-blind, randomised, placebo-controlled, crossover trial (ReBUILD) in patients with relapsing multiple sclerosis with chronic demyelinating optic neuropathy on stable immunomodulatory therapy. Patients who fulfilled international panel criteria for diagnosis with disease duration of less than 15 years were eligible. Patients were

2017 Lancet Controlled trial quality: predicted high